^
DDR
Prostate Cancer
durvalumab
Sensitive
:
C2
DDR
Cervical Cancer
BAY1895344
Sensitive
:
C2
DDR
NSCLC
PD-L1 inhibitor + CTLA4 inhibitor
Sensitive
:
C3
DDR
NSCLC
atezolizumab
Sensitive
:
C3
DDR
Cholangiocarcinoma
lenvatinib + toripalimab
Sensitive
:
C3
DDR
CRC
CAPOX
Sensitive
:
C3
DDR
CRC
FOLFOX
Sensitive
:
C3
DDR
CRC
Immunotherapy
Sensitive
:
C3
DDR
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive
:
C3
DDR
Prostate Cancer
nivolumab + ipilimumab
Sensitive
:
C3
DDR
Prostate Cancer
olaparib
Sensitive
:
C3
DDR
Prostate Cancer
abiraterone acetate
Resistant
:
C3
DDR
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive
:
C3
DDR
NSCLC
ABT-888
Sensitive
:
C3
DDR
RCC
Tyrosine kinase inhibitor
Sensitive
:
C3
DDR
Breast Cancer
Immunotherapy
Sensitive
:
C3
DDR
Bladder Cancer
Immunotherapy
Sensitive
:
C3
DDR
Melanoma
Immunotherapy
Sensitive
:
C3
DDR
Prostate Cancer
talazoparib
Sensitive
:
C3
DDR
Prostate Cancer
olaparib + abiraterone acetate
Sensitive
:
C4
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our